Clinical trial · Interventional
Rituximab in Metastatic Melanoma
Efficacy and Safety of Rituximab, an Anti-CD20 (Cluster of Differentiation Antigen 20) Therapeutic Agent, in Metastatic Melanoma: a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): the only reason is that recruitment was not sufficient to meet the planned patient numbers, because complete remissions are still infrequent.
Summary
Brief summary (as posted)
The purpose of this study is to determine whether rituximab as an adjuvant therapy in clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer) 2002) melanoma patients is safe and prolongs overall survival and disease-free interval.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- rituximab
- interventionNames
- Drug: rituximab
Primary outcomes (1)
- measure
- disease-free interval
- timeFrame
- 42 months
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 42 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically verified non-ocular melanoma stage IIIc/IV, no evidence of disease Exclusion Criteria: * ECOG (Eastern Cooperative Oncology Group) performance status \> 2 * Ocular melanoma * Immunodeficiency syndromes or hypogammaglobulinaemia * Active autoimmune diseases * Treatment with immunosuppressive agents other than steroids * Depressed bone marrow function (Leukopenia \<3000, platelet count \<100.000) * Cardiac insufficiency NYHA (New York Heart Association) IV * active Hepatitis B,C, or HIV infection * Pregnancy or lactation * Interstitial pulmonary disease * Former treatment with anti-CD20 antibody
References
Publications (0)
Data not yet available